key: cord-0968626-81up0xrr
authors: Yasuda, Hajime; Mori, Yosuke; Chiba, Asako; Bai, Jie; Murayama, Goh; Matsushita, Yasushi; Miyake, Sachiko; Komatsu, Norio
title: Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections
date: 2021-07-18
journal: Clin Lymphoma Myeloma Leuk
DOI: 10.1016/j.clml.2021.07.004
sha: 630290416a6494ba6135f41ec3028c262193f53b
doc_id: 968626
cord_uid: 81up0xrr

Background: We previously reported elsewhere of a follicular lymphoma patient suffering from persistent COVID-19 pneumonia that was still ongoing at 2 months after onset. Materials and Methods: We provide a follow-up report of the case along with a literature review of immunocompromised lymphoma patients experiencing prolonged COVID-19 infections. Results: Although requiring a full 1 year, the presented case eventually achieved spontaneous resolution of COVID-19 pneumonia. Anti-SARS-CoV-2 antibodies could not be detected throughout the disease course, but COVID-19-directed T-cell response was found to be intact. The patient also developed secondary immune thrombocytopenia subsequent to COVID-19 pneumonia. We found 19 case reports of immunocompromised lymphoma patients with prolonged COVID-19 infections in the literature. All 5 patients who died did not receive convalescent plasma therapy, whereas resolution of COVID-19 infection was achieved in 8 out of 9 patients who received convalescent plasma therapy. Conclusions: We demonstrate through the presented case that while time-consuming, resolution of COVID-19 infections may be achieved without aid from humoral immunity if cellular immunity is intact. Immunocompromised lymphoma patients are at risk of a prolonged disease course of COVID-19, and convalescent plasma therapy may be a promising approach in such patients. Micro-abstract: Persisting clinical infections and prolonged viral shedding of COVID-19 in immunocompromised patients is a rapidly emerging issue of concern. Persisting COVID-19 infections not only threaten the well-being of the patient, but may also be a potential long-term contagious threat to the environment, and special care must be provided concerning in-hospital isolation and self-quarantine periods. We report an immunocompromised lymphoma patient recovering from a 1-year disease course of COVID-19 pneumonia along with a review of the literature.

We previously reported a follicular lymphoma patient on rituximab maintenance therapy suffering from persistent COVID-19 pneumonia that was still active at 2 months after disease onset. 1 This is a follow-up report describing the resolution after a 1-year disease course of COVID-19 pneumonia and subsequent development of COVID-19-associated secondary immune thrombocytopenia (ITP).

A literature review of 19 case reports concerning prolonged COVID-19 infections in immunocompromised lymphoma patients is also provided.

This study was conducted in accordance with the Declaration of Helsinki, and the patient gave written informed consent. CD4 + and CD8 + T-cell responses against SARS-CoV-2 antigens were assessed by using an activation-induced marker assay. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence of peptide pools of spike protein (mixture of S, S+, and S1), membrane protein, and nucleocapsid of SARS-CoV-2, as well as cytomegalovirus pp65 protein (all from Miltenyi Biotec, Bergisch Gladbach, Germany). Twenty-two hours later, PBMCs were stained with the Zombie Yellow Fixable Viability Kit (Biolegend, San Diego, CA, USA) and monoclonal antibodies against human cell-surface antigens including CD3, CD4, CD8, CD137 (4-1BB), OX40, and CD69 (all from Biolegend). Data were acquired on a FACS LSR Fortessa (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using Flowjo software (TreeStar Inc., Ashland, OR, USA).

Antigen-reactive cells were identified based on the co-expression of two activation markers: OX40 and CD137 for CD4 + T-cells and CD69 and CD137 for CD8 + T-cells.

For the literature review, a MEDLINE database search through PubMed was carried out using key words "lymphoma" or "lymphocytic" in combination with either "prolonged COVID-19" or "persisting COVID-19". Only English reports were considered. The most recent PubMed search was conducted in May 2021. A total of 19 case reports including the current case of prolonged COVID-19 infections were extracted and summarized in Table 1 Repetitive immunoglobulin replacement therapy was continued in the patient, and IgG levels were maintained at around 500-800 mg/dl. Although the COVID-19 pneumonia resolved, the patient's platelet counts started to decrease around September 2020, and subsequently plateaued at around 30 × 10 9 /L as of February 2021. Bone marrow evaluation along with other screening tests were carried out in February 2021, but causes of thrombocytopenia including recurrence of follicular lymphoma could not be detected, and she was diagnosed with COVID-19-associated secondary ITP. Urea breath test was negative, and thus Helicobacter pylori infection could not be confirmed. She is currently doing well as an outpatient, and the ITP is being observed with no treatment.

We describe the disease course of COVID-19 pneumonia requiring an astonishing 1 year for recovery in a follicular lymphoma patient undergoing preceding anti-CD20 antibody therapy. IgG levels continued to rise with time despite that the dose and frequency of immunoglobulin replacement therapy was fixed as of September 2020, implying a recovering humoral immunity.

However, the patient failed to develop anti-SARS-CoV-2 IgG and IgM antibodies throughout the disease course. Furthermore, up until March 2021, we tested for anti-SARS-CoV-2 IgG and IgM antibodies within the immunoglobulin preparations used for immunoglobulin replacement therapy whenever we encountered a new product lot, but all lots were found to be negative. Thus, the eventual recovery from COVID-19 pneumonia was most likely accomplished without aid from external anti-SARS-CoV-2 antibody supplementation and patient-derived humoral immunity. Also, COVID-19-directed treatment was carried out only for the first 2 weeks according to a clinical trial to which she failed to respond, and thus the eventual recovery 1 year later was accomplished spontaneously.

We observed robust SARS-CoV-2-specific T-cell responses in PBMCs of the patient collected 1

year after diagnosis of COVID-19. The percentages of spike or nucleocapsid-specific CD4 + T-cells were even higher than that of CMV-specific CD4 + T-cells (positive control). It can be speculated that strong SARS-CoV-2-specific T-cell responses were generated because of the chronic exposure to the virus, and that cellular immunity most probably played an important role in the clearance of the virus.

Persisting clinical infection and prolonged viral shedding of COVID-19 in immunocompromised patients is a rapidly emerging issue of concern. Including the presented case, 19 case reports of prolonged COVID-19 infections occurring in immunocompromised lymphoma patients have been reported and are summarized in Table 1 Another interesting aspect of the presented case is the development of ITP. ITP is a disorder in which platelet destruction and impaired platelet production occurs due to pathogenic autoantibodies directed towards platelets and megakaryocytes. As is the case with many viral infections, COVID-19 has also been reported to trigger ITP, and one case has been reported to develop persistent ITP ongoing for more than 7 months. 25-27 The situation found in our patient is perplexing, because despite failure to develop anti-SARS-CoV-2 antibodies, in theory, the patient managed to develop pathogenic autoantibodies causing ITP.

In conclusion, we report an immunocompromised lymphoma patient suffering from a prolonged COVID-19 infection that required a full 1 year for recovery. The patient failed to develop anti-SARS-CoV-2 antibodies throughout the disease course, but a robust SARS-CoV-2-specific T-cell response was confirmable. Thus, we demonstrate that even with an impaired humoral immunity, an intact cellular immunity alone was capable of overcoming COVID-19 infection.

However, cases failing to accomplish seroconversion are at risk of persistent COVID-19 infections, and as our literature review shows, administration of convalescent plasma early in the disease course may be a rational and effective treatment approach for such patients. Prolonged infections occurring in the immunocompromised not only threaten the well-being of the patient, but may also be a potential long-term contagious threat to others, and special care must be provided concerning in-hospital isolation and self-quarantine periods.

The authors have stated that they have no conflicts of interest.

Clinical practice points  Immunocompromised lymphoma patients are at risk of abnormally prolonged COVID-19 infections.

 Anti-SARS-CoV-2 antibodies are most often absent in such patients, and convalescent plasma therapy may be an effective treatment approach.

 Persisting COVID-19 infections not only threaten the well-being of the patient, but may also be a potential long-term contagious threat to the environment, and special care must be provided concerning in-hospital isolation and self-quarantine periods. 

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma

Targets of T Cell Responses to SARS-CoV-2

Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Persistent COVID-19 in an

Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Case Report: A Patient with COVID-19 under Myelosuppression Induced by Chemotherapy

Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient

Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir

Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency

Acute SARS-CoV-2 pneumonitis with cytotoxic CD8 positive T-lymphocytes: Case report and review of the literature

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

Delayed COVID-19 Respiratory Failure in Patients with

Lymphoma on Rituximab-based Chemoimmunotherapy

Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy

Convalescent plasma therapy for

B-cell-depleted patients with protracted COVID-19